Phanes Therapeutics Announces the Appointment of Gastrointestinal Oncologist Prof. Zev Wainberg to its Clinical Advisory Board
'We are excited to have Professor Wainberg joining our Clinical Advisory Board,' said Ming Wang, PhD, MBA, Phanes' Chief Executive Officer. 'Dr. Wainberg is a leading medical oncologist in gastrointestinal malignancies. He will join the other leading experts on our CAB to provide valuable guidance and advice on the three clinical programs at Phanes. His extensive expertise and experience will enhance Phanes' strength in drug development and ability to deliver innovative therapies for cancer patients.'
Biograph of Professor Zev Wainberg
Zev Wainberg, MD
Dr. Wainberg is an academic medical oncologist at the David Geffen UCLA School of Medicine specializing in gastrointestinal malignancies. He currently serves as the co-director of the GI oncology program and medical director of the Pancreas Cancer Center at UCLA with a joint appointment in medicine and surgery. His research focus is on translational research of GI cancers with a particular focus on drug development. He also serves as the director of the Early Phase Clinical Research Program at the Jonsson Comprehensive Cancer Center at UCLA. He is currently the principal investigator on over 25 clinical trials focused on targeted therapeutics in patients with gastrointestinal cancers.
Full CAB information at https://www.phanesthera.com/about-us/cab/.
ABOUT PHANES THERAPEUTICS
Phanes Therapeutics, Inc. is a clinical stage biotech company focused on innovative drug discovery and development in oncology. Currently, it is conducting three Phase I clinical trials, including the MORNINGSTAR study with its best-in-class monoclonal antibody (mAb) program, PT199, the TWINPEAK study with PT886 and the SKYBRIDGE study with PT217. Both PT886 and PT217 are first-in-class bispecific antibodies and have been granted orphan drug designation as well as Fast Track designation by the FDA.
The company has built a strong pipeline by leveraging its proprietary technology platforms: PACbody®, SPECpair® and ATACCbody® to develop novel biologics that address high unmet medical needs in cancer.
For more information about Phanes Therapeutics, please visit www.phanesthera.com.
Hashtags
- BusinessHealthScienceFinance#PT886,PT217,therapeutics,MORNINGSTAR,PT199,TWINPEAK,SKYBRIDGE,PACbody,SPECpair,ATACCbody,ZevWainberg,Wainberg,MingWang,UCLA,Phanes,ClinicalAdvisoryBoard,CAB,Phanes',PRNewswire,PhanesTherapeutics,Inc,DavidGeffenSchoolofMedicine,DavidGeffenUCLASchoolofMedicine,PancreasCancerCenter,JonssonComprehensiveCancerCenter,PHANESTHERAPEUTICS,PhanesTherapeutics,Inc.,FDA,PhanesTherapeutics
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
an hour ago
- Miami Herald
CVS, Target, Walmart: Which sell Plan B and/or the abortion pill?
Costco Wholesale has decided to not sell the abortion pill mifepristone across all its U.S. pharmacy stores, citing low demand. This isn't a change in policy or Costco (COST) dropping the medicine. It has never sold mifepristone in its warehouse clubs or through its pharmacies. "Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers," Costco said. The decision comes amid campaigns against the pill by religious activist groups, including Inspire Investing and Alliance Defending Freedom. Plan B (Levonorgestrel) Purpose: Emergency contraception to prevent pregnancy after unprotected sex or contraceptive failure (e.g., condom break). When used:Before a pregnancy starts, within 72 hours (best within 24 hours) after sex. How it works: Delays or prevents ovulation (egg release). May also prevent fertilization of the egg. Does not terminate an existing pregnancy. If the fertilized egg is already implanted, Plan B has no effect. Type: High-dose progestin (hormone), similar to birth control pill hormones, just in a single larger dose. Availability: Over-the-counter, no prescription, no age limit in the U.S. The Abortion Pill (Mifepristone + Misoprostol) Purpose: To end an existing pregnancy (up to about 10–11 weeks gestation in the U.S.). When used:After pregnancy has been confirmed (positive test or clinical confirmation). How it works:Mifepristone blocks progesterone, a hormone needed to maintain pregnancy. Misoprostol causes the uterus to contract and expel the pregnancy tissue. Type: Two different medications taken in sequence - not the same as hormonal birth control. Availability: Requires a prescription in the U.S. and is regulated under the FDA's Mifepristone REMS Program (dispensed at certified pharmacies, clinics, or by mail in states where legal). CVS: Stocked in most locations, typically in the family planning aisle; billing through insurance is possible, or pay out-of-pocket and claim later. You can also order online for Commonly available either on shelves or behind the counter; curbside and drive-thru pick-up may be offered Target: Carries Plan B both in-store and online, with options for delivery or same-day in-store Available in the family planning or sexual wellness section; online ordering with pickup or delivery options is also grocery and drugstore chains: Many large grocery store pharmacies (Kroger, Albertsons) and drugstore chains carry Plan B over-the-counter near other reproductive health retail pharmacies CVS and Walgreens: These two major chains have obtained FDA certification (through the Mifepristone REMS program) to dispense mifepristone in select locations, specifically in states where such dispensing is legally permitted. The list includes over 20 states such as California, New York, Illinois, Massachusetts, Pennsylvania, and others. However, availability varies by location and state-level restrictions Costco has said its decision on the abortion pill is a business one based on demand. The company generally stays out of politics. It has a very clear policy on its website: Costco Wholesale has a long-standing policy against making contributions to any political party or candidate, federal, state or local, in all countries in which we do business. This prohibition covers not only direct contributions, but also support through organizations created under section 527 of the Internal Revenue Code, buying tickets to political fundraising events, or furnishing goods, services, or equipment for political fundraising Company also prohibits contributions for "independent expenditures": communications that expressly advocate the election or defeat of a clearly identified candidate that are not made in cooperation, consultation, or concert with, or at the request or suggestion of, a candidate, candidate's authorized committee, or a political party. Related: Costco to keep abortion pill off shelves amid conservative outcry The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
Epoch Times
2 hours ago
- Epoch Times
Malfunctioning Insulin Pumps Recalled After 59 Injuries
San Diego-based Tandem Diabetes Care, Inc. is voluntarily recalling insulin pumps used to manage blood sugar, the company said in an Aug. 12 announcement by the Food and Drug Administration. Insulin pumps are wearable devices that deliver insulin at predetermined doses at specific times. Such devices can feature alarm functions to alert users about various situations, such as issues with insulin delivery.
Business Insider
4 hours ago
- Business Insider
J.P. Morgan Reaffirms Their Buy Rating on Mebuki Financial Group, Inc. (7167)
J.P. Morgan analyst Takahiro Yano maintained a Buy rating on Mebuki Financial Group, Inc. yesterday and set a price target of Yen1,110.00. The company's shares closed yesterday at Yen912.20. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Yano is a 5-star analyst with an average return of 33.1% and an 88.64% success rate. Yano covers the Financial sector, focusing on stocks such as Resona Holdings, Sumitomo Mitsui Holdings, and SBI Holdings. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mebuki Financial Group, Inc. with a Yen1,110.00 average price target. Based on Mebuki Financial Group, Inc.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of Yen78.64 billion and a net profit of Yen9.12 billion. In comparison, last year the company earned a revenue of Yen67.73 billion and had a net profit of Yen11 billion
